Serología del virus de la hepatitis B: para múltiples escenarios, múltiples exámenes
DOI:
https://doi.org/10.22516/25007440.327Palabras clave:
virus B, infección oculta, anti-core, reactivaciónResumen
El virus de la hepatitis B (VHB) tiene un gran impacto mundial. No obstante la disponibilidad de la vacuna, 2000 millones de personas se han infectado agudamente y, de ellos, 240 millones persisten crónicamente infectados. La infección tiene diferentes formas de presentación tales como infección aguda, infección crónica, infección oculta y reactivación cuando hay inmunosupresión. Así mismo, hay marcadores muy sensibles como el anticore, cuya positividad puede tener diversos significados. El recientemente descrito antígeno relacionado con el antígeno core es un marcador emergente que podría reemplazar al ácido desoxirribonucleico (ADN) viral. En la presente revisión se discuten los exámenes de laboratorio necesarios para el diagnóstico de los diferentes escenarios de la infección.
Descargas
Lenguajes:
esReferencias bibliográficas
World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. [internet] 2018 [acceso el 1 de marzo de 2018]. Disponible en: https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/
World Health Organization. Hepatitis B. [internet] 2018 [acceso el 1 de marzo de 2018]. Disponible en: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016:388;1081-8.
Peeridogaheh H, Meshkat Z, Habibzadeh S, Arzanlou M, Shahi JM, Rostami S, et al. Current concept on immunopathogesis of hepatitis B virus infection. Vir Res. 2018;245:29-43. doi: 10.1016/j.virusres.2017.12.007.
Sandhu P, Haque M, Humphries-Bickley T, Ravi S, Song J. Hepatitis B virus immunopathology, model systems, and current therapies. Front Immunol. 2017;8: Article 436. doi: 10.3389/fimmu.2017.00436.
Li X, Zhao J, Yuan Q, Xia N. Detection of HBV Covalently Closed Circular DNA. Viruses. 2017;9(6). pii: E139. doi: 10.3390/v9060139.
Valaydos ZS, Locarnini SA. The virological aspects of hepatitis B. Best Pract Res Clin Gastroenterol. 2017;31:257-64. doi: 10.1016/j.bpg.2017.04.013.
Yang S, Wang D, Zhang Y, Yu C, Ren J, Xu K, et al. Transmission of Hepatitis B and C Virus Infection Through Body Piercing: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015;94(47):e1893. doi: 10.1097/MD.0000000000001893.
Yuen MF, Ahn SH, Chen DS, Chen PJ, Dusheiko GM, Hou JL, et al. Chronic hepatitis B virus infection. Disease revisited and management recommendations. J Clin Gastroenterol. 2016;50:286-94. doi: 10.1097/MCG.0000000000000478.
Fattocich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335-52. doi: 10.1016/j.jhep.2007.11.011.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of 2080 worldwide prevalence of chronic hepatitis B virus infection: A systematic 2081 review of data published between 1965 and 2013. Lancet 2015;386:1546–55. doi: 10.1016/S0140-6736(15)61412-X.
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128. doi: 10.1016/S0140-6736(12)61728-0.
Seeger C, Mason W. Molecular biology of hepatitis B virus infection. Virology. 2015;479-480:672-86. doi: 10.1016/j.virol.2015.02.031.
Trepo C, Chan H, Lok A. Hepatitis B virus infection. Lancet. 2014;384 (9959):2053-63. doi: 10.1016/S0140-6736(14)60220-8.
Villar LM, Medina-Cruz H, Ribeiro-Barbosa J, Souz-Bezerra C, Machado-Portilho M, Scalioni L. Update on hepatitis B and C virus diagnosis. World J Virol. 2015;4(4):323-42. doi: 10.5501/wjv.v4.i4.323.
Pondé RAA. Acute hepatitis B virus infection or cute exacerbation of chronic hepatitis B infection: the differential serological diagnosis. Eur J Clin Microbiol Infect Dis. 2016;35:29-40. doi: 10.1007/s10096-015-2522-7.
Durantel D. New treatments to reach functional cure: virological approaches. Best Pract res Clin Gastroenterol 2017;31:329-36. doi: 10.1016/j.bpg.2017.05.002.
Valaydon ZS, Locarnini SA. The virological aspects of hepatitis B. Best Pract Res Clin Gastroenterol. 2017;31:257-64. doi: 10.1016/j.bpg.2017.04.013.
Hong X, Kim ES, Guo H. Epigenetic regulation of hepatitis B virus covalently closed circular DNA: implications for epigenetic therapy against chronic hepatitis B. Hepatology 2017;66(6):2066-77. doi: 10.1002/hep.29479.
Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol. 2016;64:S117-31. doi: 10.1016/j.jhep.2016.02.016.
Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, et al. Towards an HBV cure: state of the art and unresolved questions-report of the ANRS workshop on HBV cure. Gut. 2015;64(8):1314-26. doi: 10.1136/gutjnl-2014-308943.
Schreiner S, Nassal M. A role for the host DNA damage response in hepatitis B virus cccDNA formation and beyond? Viruses. 2017;9(5):125. doi: 103390/v9050125.
Han Y, Tang Q, Zhu W, Zhang Y, You L. Clinical, biochemical, immunological and virological profiles of and differential diagnosis between, patients with acute hepatitis B and chronic hepatitis B with acute flare. J Gastroenterol Hepatol. 2008;23:1728-33. doi: 10.1111/j.1440-1746.2008.05600.x.
Kumar M, Jain S, Sharma BC, Sarin SK. Differentiating acute hepatitis B from the first episode of symptomatic exacerbation of chronic hepatitis B. Dig Dis Sci. 2006;51(3):594-9. doi: 10.1007/s10620-006-3175-2.
Lin CJ, Kao JH. Natural history of acute and chronic hepatitis B: the role of HBV genotypes and mutants. Best Pract Res Clin Gastroenterol. 2017;31:249-55. doi: 10.1016/j.bpg.2017.04.010.
Beasley RP. Rocks along the road to the control of HBV and HCC. Ann Epidemiol 2009; 19:231-4. doi: 10.1016/j.annepidem.2009.01.017.
Sherlock S. The natural history of hepatitis B. Postgrad Med J. 1987;63:7-11.
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-98. doi: 10.1016/j.jhep.2017.03.021.
Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341:22-6. doi: 10.1056/NEJM199907013410104.
Raimondo G, Allain JP, Brunetto MR, Buendía MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49:652-7. doi: 10.1016/j.jhep.2008.07.014.
Kwak MS, Kim YJ. Occult hepatitis B virus infection. World J Hepatol. 2014;6(12):860-9. doi: 10.4254/wjh.v6.i12.860.
Kang SY, Kim MH, Lee WI. The prevalence of “ati-HBc alone” and HBV DNA detection among anti –HBc alone en Korea. J Med Virol. 2010;82:16508-14. doi: 10.1002/jmv.21862.
Yuen MF, Lee CK, Wong DK, Fung J, Hung I, Hau A, et al. Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. Gut 2010; 59:1389-93. doi: 10.1136/gut.2010.209148.
Makvandi M. Update on occult hepatitis B virus infection World J Gastroenterol. 2016;22(39):8720-34. doi: 10.3748/wjg.v22.i39.8720.
Sagnelli C, Macera M, Pisaturo M, Zampino R, Coppola M, Sagnelli E. Occult HBV infection in the oncohematological setting. 2016; 44(5):575-82. doi: 10.1007/s15010-016-0891-1.
Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di VP, et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008; 134:1470-81. doi: 10.1053/j.gastro.2008.02.017.
Mulrooney-Cousins PM, Michalack TI. Persistent occult hepatitis B virus infection:experimental findings and clinical implications. World J Gastroenterol. 2007;13:5682-6. doi: 10.3748/wjg.v13.i43.5682.
Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Sem Immunopathol. 2013;35:39-52. doi: 10.1007/s00281-012-0327-7.
Mohsen W, Levy MT. Hepatitis A to E: what’s new? Intern Med J. 2017;47:380-9. doi: 10.1111/imj.13386.
Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33:619-33. doi: 10.1111/j.1365-2036.2010.04570.x.
Melmed GY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflam Bowel Dis. 2009;15:1410-6. doi: 10.1002/ibd.20943.
Squadrito G, Spinella R, Raimondo G. The clinical significance of occult HBV infection. Ann Gastroenterol. 2014;27(1):15-9.
Fabbri G, Mastrorosa I, Vergori A, Mazzotta V, Pinnetti C, Grisetti S, et al. Reactivation of occult HBV infection in an HIV /HCV co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature. BMC infect Dis. 2017;17:182. doi: 10.1186/s12879-017-2287-y.
Chen G, Wang C, Chen J, Ji D, Wang Y, Wu V, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis. Hepatology. 2017;66(1):13-26. doi: 10.1002/hep.29109.
Perrillo RP. Hepatitis B virus reactivation during direct-acting antiviral treatment of chronic hepatitis C: A hidden danger of an otherwise major success story. Hepatology. 2017;66(1):4-6. doi: 10.1002/hep.29185.
Food and Drug Administration. FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. FDA [internet] 2016 [acceso el 27 de diciembre de 2017]. Disponible en: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM523499.pdf
Zhou K, Terrault N. Management of hepatitis B in special populations. Best Pract Res Clinl Gastroenterol. 2017;31:311-20. doi: 10.1016/j.bpg.2017.06.002.
Milich DR, McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science. 1986;234:1398–1401. doi: 10.1126/science.3491425.
Busch MP. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? Tranfus Clin Biol. 2004;11(1):26–32. doi: 10.1016/j.tracli.2003.12.003.
Wang Q, Klenerman P, Semma N. Significance of anti-HBc alone serological status in clinical practice. Lancet Gastroenterol Hepatol. 2017;2(2):123-34. doi: 10.1016/S2468-1253(16)30076-0.
Wu T, Kwok RM, Tran TT. Isloated anti HBc: the relevance of hepatits B core antibody: a review of new issues. Am J Gastroenterol 2017;112:1780-8. doi: 10.1038/ajg.2017.397.
Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology. 2000;31(2):488-95. doi: 10.1002/hep.510310232.
Berger A, Doerr HW, Rabenau HF, Weber B. High frequency of HCV infection in individuals with isolated antibody to hepatitis B core antigen. Intervirology 2000;43:71-6. doi: 10.1159/000025026.
Marusawa H, Osaki Y, Kimura T, Ito K, Yamashita Y, Eguchi T, et al. High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan. Gut. 1999;45(2):284-8. doi: 10.1136/gut.45.2.284.
Jilg W, Sieger E, Zachoval R, Schätzl H. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol. 1995;23(1):14-20.
Wedemeyer H, Cornberg M, Tietmeyer B. Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication. Clin Microbiol Infect. 2004;10:70-2. doi: 10.1111/j.1469-0691.2004.00771.x.
Chu CM, Yeh CT, Liaw YF. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J Clin Microbiol. 1998;36:2084-6.
Wagner AA, Denis F, Weinbreck P, Loustaud V, Autofage F, Rogez S, et al. Serological pattern ‘anti-hepatitis B core alone’ in HIV or hepatitis C virus-infected, patients is not fully explained by hepatitis B surface antigen mutants. AIDS. 2004;18(3):569-71. doi: 10.1097/00002030-200402200-00028.
Piroth L, Binquet C, Vergne M, Minello A, Livry C, Bour JB, et al. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol. 2002;36(5):681-6.
Loustaud-Ratti V, Wagner A, Carrier P, Marczuk V, Chemin I, Lunel F, et al. Distribution of total DNA and cccDNA in serum and PBMCs may reflect the HBV immune status in HBsAg+ and HBsAg- patients coinfected or not with HIV or HCV. Clin Res Hepatol Gastroenterol. 2013;37(4):373-83. doi: 10.1016/j.clinre.2012.11.002.
Pondé RA, Cardoso DD, Ferro MO. The underlying mechanisms for the ‘anti-HBc alone’ serological profile. Arch Virol. 2010;155(2):149-58. doi: 10.1007/s00705-009-0559-6.
Parkinson AJ, McMahon BJ, Hall D, Ritter D, Fizgerald MA. Comparison of enzyme immunoassay with radioimmunoassay for the detection of antibody to hepatitis core antigen as the only marker of hepatitis B infection in a population with a high prevalence of Hepatitis B. J Med Virol. 1990;30:253-7. doi: 10.1002/jmv.1890300405.
Silva AE, McMahon BJ, Parkinson AJ, Sjögren MH, Hoofnagle JH, Di Bisceglie AM. Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. Clin Infect Dis. 1998;26:895-7. doi: 10.1086/513918.
Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet. 1975;2:528-30. doi: 10.1016/S0140-6736(75)90897-1.
Nagingthon J. Reactivation of hepatitis B after transplantation operations. Lancet. 1977;1:558-60. doi: 10.1016/S0140-6736(77)91995-X.
Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg Quantification to Optimize Treatment Monitoring in Chronic Hepatitis B Patients. Liver Int. 2015;35(Suppl 1):82-90. doi: 10.1111/liv.12735.
Di Bisceglie AM, Lok AM, Martin P, Terrault N, Perillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppresing and anticancer drugs: just the tip of the iceberg?. Hepatology. 2015;61(2):703-11. doi: 10.1002/hep.27609.
Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:221-44. doi: 10.1053/j.gastro.2014.10.038.
Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter Y. American Gastroenterological Association Institute Guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148:215-9. doi: 10.1053/j.gastro.2014.10.039.
Bessone F, Dirchwolf M. Management of hepatitis B reactivation in immunosupressed patients: an update on current recommendations. World J Hepatol. 2016;8(8)385-94. doi: 10.4254/wjh.v8.i8.385.
Lau GKK. How do we handle the ant-HBc positive patient (in highly endemic settings): The Anti-HBc positive patient. Clinical Liver Disease 2015;5:29-31. doi: 10.1002/cld.399.
American Gastroenterological Association. AGA Institute guidelines on Hepatitis B reactivation (HBVr): Clinical Decision Support Tool. Gastroenterology. 2015;148(1):220. doi: 10.1053/j.gastro.2014.11.040.
Paul S, Dickstein A, Saxena A, Terrin N, Viveiros K, Balk EM, et al. Role of Surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis. Hepatology 2017;66 (2):379-88. doi: 10.1002/hep.29082.
Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, et al. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol. 2012;91(7):1007-12. doi: 10.1007/s00277-012-1405-6.
Mozessohn L, Chan KK, Feld JJ, Hicks LK. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat. 2015;22:842-9. doi: 10.1111/jvh.12402.
Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology. 2017;152(6):1297-309. doi: 10.1053/j.gastro.2017.02.009.
Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med 2016; 164:30–40. doi: 10.7326/M15-1121.
Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, et al. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: the PREBLIN study. Plon One. 2017;12(9):e0184550. doi: 10.1371/journal.pone.0184550.
Kwak YE, Stein SM, Lim JK. Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network. Dig Dis Sci. 2018;63(1):61-71. doi: 10.1007/s10620-017-4850-1.
Mak LY, Wong DKH, Cheung KS, Seto WK, Lai CL, Yiuen MF. Hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2018;47:43-54. doi: 10.1111/apt.14376.
Ji M, Hu K. Recent advances in the study of hepatitis B virus covalently closed circular DNA. Virol Sin. 2017;32(6):454-464. doi: 10.1007/s12250-017-4009-4.
Kimura T, Rojuhara A, Sakamoto Y. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol. 2002;40:439-45. doi: 10.1128/JCM.40.2.439-445.2002.
Wang DK, Seto WK, Cheung KS. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Intern. 2017;37:995-1001. doi: 10.1111/liv.13346.
Lai CL, Wong DP. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017;66:275-1. doi: 10.1016/j.jhep.2016.08.022.
Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62(3):299-307.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
| Estadísticas de artículo | |
|---|---|
| Vistas de resúmenes | |
| Vistas de PDF | |
| Descargas de PDF | |
| Vistas de HTML | |
| Otras vistas | |
